Literature DB >> 6487395

Clinical and pathologic studies of synovitis in polymyalgia rheumatica.

C T Chou, H R Schumacher.   

Abstract

Clinically detectable joint swelling was found in 10 of 13 fully evaluated patients considered to have polymyalgia rheumatica. Five patients had some joint findings at disease onset. Knees were most commonly affected. Sternoclavicular involvement was seen in 3 patients. Joint effusions in 8 patients had 300-5,700 leukocytes/mm3 with a mean of 2,900. Six synovial biopsy specimens studied by light microscopy revealed mild to moderate synovial proliferation and chronic inflammation that was generally less severe than in typical rheumatoid arthritis. Electron microscopy identified microvascular changes and large amounts of vesicular and granular debris in lining cells. In 1 patient, a "fingerprint" pattern in the granular material was suggestive of the findings in some immune complexes. This still unexplained synovitis may, as previously suggested, be important in the pathogenesis of the polymyalgia rheumatica syndrome.

Entities:  

Mesh:

Year:  1984        PMID: 6487395     DOI: 10.1002/art.1780271005

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  4 in total

Review 1.  The role of imaging in polymyalgia rheumatica/giant cell arteritis.

Authors:  William S Wilke
Journal:  Skeletal Radiol       Date:  2008-09       Impact factor: 2.199

2.  HLA antigens in polymyalgia rheumatica in northern Sweden.

Authors:  A Uddhammar; B N Sojka; S Rantapää-Dahlqvist
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

3.  An 80-Year-Old Man With Fevers, Altered Mental Status, and Joint Effusions.

Authors:  Naomi Serling-Boyd; Zachary Wallace; Jana Jarolimova; Sheila Arvikar; Eli M Miloslavsky
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-03       Impact factor: 4.794

4.  Rarity of synovitis in polymyalgia rheumatica.

Authors:  V Kyle; J Tudor; E P Wraight; G A Gresham; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.